Form 4: Pitofsky Jason reports multiple insider transactions in REGN

Rhea-AI Filing Summary

Pitofsky Jason reported multiple insider transaction types in a Form 4 filing for REGN. The filing lists transactions totaling 4,036 shares at a weighted average price of $684.14 per share. Following the reported transactions, holdings were 6,308 shares.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Pitofsky Jason

(Last) (First) (Middle)

777 OLD SAW MILL RIVER ROAD

(Street)

TARRYTOWN NY 10591

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
REGENERON PHARMACEUTICALS, INC. [ REGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP Controller

3. Date of Earliest Transaction (Month/Day/Year)
02/09/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/09/2026		M(1)		1,000	A	$492	6,308	D
Common Stock	02/09/2026		S(1)		20	D	$775.95	6,288	D
Common Stock	02/09/2026		S(1)		521	D	$776.43(2)	5,767	D
Common Stock	02/09/2026		S(1)		391	D	$777.51(3)	5,376	D
Common Stock	02/09/2026		S(1)		563	D	$778.35(4)	4,813	D
Common Stock	02/09/2026		S(1)		205	D	$779.56(5)	4,608	D
Common Stock	02/09/2026		S(1)		75	D	$780.06(6)	4,533	D
Common Stock	02/09/2026		S(1)		26	D	$781.37(7)	4,507	D
Common Stock	02/09/2026		S(1)		37	D	$782.67(8)	4,470	D
Common Stock	02/09/2026		S(1)		144	D	$783.23(9)	4,326	D
Common Stock	02/09/2026		S(1)		1	D	$784.66	4,325	D
Common Stock	02/09/2026		S(1)		53	D	$785.72(10)	4,272	D
Common Stock								31	I	By 401(k) Plan
Common Stock								179	I	by Spouse

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non-Qualified Stock Option (right to buy)	$492	02/09/2026		M(1)			1,000	(11)	12/09/2030	Common Stock	1,000	$0.0	905	D

Explanation of Responses:

1. Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on November 10, 2025.

2. Represents volume-weighted average price of sales of 521 shares of Company stock on February 9, 2026 at prices ranging from $776.05 to $776.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2026 at each separate price.

3. Represents volume-weighted average price of sales of 391 shares of Company stock on February 9, 2026 at prices ranging from $777.33 to $777.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2026 at each separate price.

4. Represents volume-weighted average price of sales of 563 shares of Company stock on February 9, 2026 at prices ranging from $778.00 to $778.95. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2026 at each separate price.

5. Represents volume-weighted average price of sales of 205 shares of Company stock on February 9, 2026 at prices ranging from $779.19 to $779.96. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2026 at each separate price.

6. Represents volume-weighted average price of sales of 75 shares of Company stock on February 9, 2026 at prices ranging from $780.03 to $780.65. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2026 at each separate price.

7. Represents volume-weighted average price of sales of 26 shares of Company stock on February 9, 2026 at prices ranging from $781.18 to $781.53. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2026 at each separate price.

8. Represents volume-weighted average price of sales of 37 shares of Company stock on February 9, 2026 at prices ranging from $782.22 to $782.83. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2026 at each separate price.

9. Represents volume-weighted average price of sales of 144 shares of Company stock on February 9, 2026 at prices ranging from $783.17 to $783.29. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2026 at each separate price.

10. Represents volume-weighted average price of sales of 53 shares of Company stock on February 9, 2026 at prices ranging from $785.72 to $785.73. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2026 at each separate price.

11. The stock option award vested in four equal annual installments, commencing one year after the date of grant.

	/s/ Jason Pitofsky	02/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Regeneron (REGN) report for Jason Pitofsky?

Regeneron disclosed that SVP Controller Jason Pitofsky exercised a non-qualified stock option for 1,000 common shares at $492 per share and then sold multiple small blocks of common stock in open-market transactions around $776–$786 per share on February 9, 2026 under a Rule 10b5-1 plan.

How many Regeneron shares does Jason Pitofsky own after this Form 4?

After the reported transactions, Jason Pitofsky directly owned 4,272 shares of Regeneron common stock. He also had indirect beneficial ownership of 31 additional shares through a 401(k) plan and 179 shares held by his spouse, according to the ownership table in the filing.

What stock option activity involving Regeneron (REGN) did the Form 4 show?

The Form 4 shows Jason Pitofsky exercised a non-qualified stock option covering 1,000 shares of Regeneron common stock at a $492 exercise price. The option award vests in four equal annual installments beginning one year after grant, and 905 derivative securities remained beneficially owned after the transaction.

Were Jason Pitofsky’s Regeneron stock sales under a Rule 10b5-1 plan?

Yes. A footnote states that the dispositions and acquisition were made under a trading plan intended to comply with Rule 10b5-1(c), which was adopted on November 10, 2025. Such plans pre-schedule trades to help insiders diversify while managing potential trading-related concerns.

What prices did Jason Pitofsky receive for his Regeneron stock sales?

The reported open-market sales occurred at various volume-weighted average prices, generally around $775.95 to $785.72 per share. Footnotes explain that each average reflects multiple trades within narrow intraday price ranges and that full price-by-trade details are available upon request to the reporting person.

What is the role of Jason Pitofsky at Regeneron Pharmaceuticals?

Jason Pitofsky is identified as an officer of Regeneron Pharmaceuticals with the title "SVP Controller." This senior finance role makes him a Section 16 reporting person, requiring disclosure of his transactions in Regeneron equity securities on Form 4 under U.S. securities regulations.